Neither metformin nor sulfonylureas had any effect on gastric cancer risk (insulin vs. metformin (OR), 1.855; 95% CI: 0.779–4.419 and sulfonylurea vs. metformin (OR), 1.547; 95% CI: 0.923–2.594) [22]. Here, INS is linked to gastric cancer.